[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-332343-105":59,"doc-detail-332343-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","hormone-replacement-therapy-and-cancer-mortality-in-women-with-17-site-specific-cancers-a-cohort-study-using-linked-medical-records","Hormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records","","Limited evidence exists on the safety of hormone replacement therapy (HRT) for women who have cancer. This cohort study used linked medical records to examine HRT use after diagnosis and cancer-specific mortality across 17 site-specific cancers. Women newly diagnosed between 1998 and 2019 were identified from general practitioner records, hospital diagnoses, and cancer registries in Scotland, Wales, and England. Excluding breast cancer patients, the primary analysis assessed time to cancer-specific death using time-dependent Cox regression. No increase in cancer-specific mortality was found among systemic HRT users versus non-users.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/hormone-replacement-therapy-and-cancer-mortality-in-women-with-17-site-specific-cancers-a-cohort-study-using-linked-medical-records/332343/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/hormone-replacement-therapy-and-cancer-mortality-in-women-with-17-site-specific-cancers-a-cohort-study-using-linked-medical-records/332343.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why was this study conducted?","Question",{"text":113,"@type":114},"Evidence on the safety of hormone replacement therapy (HRT) in women with cancer was limited, and clinicians faced uncertainty about how HRT might affect cancer outcomes.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were participants and cancer diagnoses identified?",{"text":118,"@type":114},"Women newly diagnosed with 17 site-specific cancers from 1998 to 2019 were identified using general practitioner records, hospital diagnoses, and cancer registries in Scotland, Wales, and England.",{"name":120,"@type":111,"acceptedAnswer":121},"What was the main outcome and how was it analyzed?",{"text":122,"@type":114},"The primary outcome was time to cancer-specific mortality. Time-dependent Cox regression models estimated adjusted hazard ratios with 95% confidence intervals for systemic HRT use.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},332343,1790443884,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","British Journal of Cancer [www.nature.com/bjc](www.nature.com/bjc)  \nARTICLE OPEN   \nEpidemiology  \nHormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records  \nChris R. Cardwell 1 ✉, Tom A. Ranger2, Alexander M. Labeit1, Carol A. C. Coupland 3, Blánaid Hicks 1, Carmel Hughes4,Úna McMenamin 1, Xue W. Mei2, Peter Murchie 5 and Julia Hippisley-Cox 2  \n© The Author(s) 2024  \nBACKGROUND: There is limited evidence on the safety of Hormone Replacement Therapy (HRT) in women with cancer. Therefore, we systematically examined HRT use and cancer-specific mortality in women with 17 site-specific cancers.  \nMETHODS: Women newly diagnosed with 17 site-specific cancers from 1998 to 2019, were identified from general practitioner (GP) records, hospital diagnoses or cancer registries in Scotland, Wales and England. Breast cancer patients were excluded because HRT is contraindicated in breast cancer patients. The primary outcome was time to cancer-specific mortality. Time-dependent Cox regression models were used to calculate adjusted hazard ratios (HR) and 95% confidence intervals (95% CIs) for cancer-specific mortality by systemic HRT use.  \nRESULTS: The combined cancer cohorts contained 182,589 women across 17 cancer sites. Overall 7% of patients used systemic HRT after their cancer diagnosis. There was no evidence that HRT users, compared with non-users, had higher cancer-specific mortality at any cancer site. In particular, no increase was observed in common cancers including lung (adjusted HR = 0.98 95% CI 0.90, 1.07), colorectal (adjusted HR = 0.79 95% CI 0.70, 0.90), and melanoma (adjusted HR = 0.77 95% CI 0.58, 1.02) . CONCLUSIONS: We observed no evidence of increased cancer-specific mortality in women with a range of cancers (excluding breast) receiving HRT.  \nBritish Journal of Cancer (2024) 131:737–746; [https://doi.org/10.1038/s41416-024-02767-8](https://doi.org/10.1038/s41416-024-02767-8)  \nBACKGROUND  \nHormone replacement therapy (HRT) is widely used to reduce menopausal related vasomotor symptoms (hot flushes, and night sweats) [1], urogenital atrophy [1] and postmenopausal osteoporosis [2] . It has also been shown to reduce joint pain, moodswings, sleep disturbances and improve quality of life [1] . The earlier detection and improved survival of patients with cancer has led to increasing numbers of women with cancer experiencing menopausal symptoms. In the United Kingdom (UK) HRT is contraindicated in patients with breast cancer and oestrogendependent cancers [2–4] but is not contraindicated in patients with other cancers. Clinicians may be reluctant to treat menopausal symptoms in patients with cancer using HRT given uncertainty around the impact of HRT on cancer outcomes, but denial of HRT without clear indication has been criticised by some authors as it could lead to unnecessary suffering [5, 6] .  \nSome researchers summarising evidence on the safety of HRT use in patients with cancer have advised caution when prescribing HRT to patients with several cancers including bladder, gastric and lung  \ncancer [7, 8] . These recommendations were partly based on preclinical studies suggesting that oestrogen stimulates growth in bladder [9] and gastric cancer cell lines [10] and lung cancer mouse models [11] . Further, observational studies have shown increases in the risk of glioma and meningioma with use of oestrogen alone HRT [12] and the Women’s Health Initiative randomised controlled trial (RCT) showed a marked increase in death from lung cancer in theoestrogen plus progestin group compared with placebo [13] . Also, an early cohort study showed reduced survival with prior HRT use inpatients with lung cancer [14] but this was not replicated in two later studies [15, 16] . Few epidemiological studies have investigated HRT use after cancer diagnosis and cancer-specific mortality, and to the best of our knowledge none has investigated HRT use after a bladder, gastric or","cbCaimWOUsQaVwdv","https://ap.wps.com/l/cbCaimWOUsQaVwdv","pdf",691939,"English","# Background\n## Methods\n## Results\n## Conclusions\n# Methods\n## Data sources and cohort identification\n## Outcome and statistical analysis","[{\"question\":\"Why was this study conducted?\",\"answer\":\"Evidence on the safety of hormone replacement therapy (HRT) in women with cancer was limited, and clinicians faced uncertainty about how HRT might affect cancer outcomes.\"},{\"question\":\"How were participants and cancer diagnoses identified?\",\"answer\":\"Women newly diagnosed with 17 site-specific cancers from 1998 to 2019 were identified using general practitioner records, hospital diagnoses, and cancer registries in Scotland, Wales, and England.\"},{\"question\":\"What was the main outcome and how was it analyzed?\",\"answer\":\"The primary outcome was time to cancer-specific mortality. Time-dependent Cox regression models estimated adjusted hazard ratios with 95% confidence intervals for systemic HRT use.\"}]","Hormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records | PDF",1789997778,25]